Chhetri Pratima, Giri Anil, Shakya Suraj, Shakya Sujana, Sapkota Binaya, Pramod K C
Lecturer, Department of Pharmaceutical Sciences, Faculty of Health Science, Nobel College , Kathmandu, Nepal .
J Clin Diagn Res. 2016 Nov;10(11):XE01-XE05. doi: 10.7860/JCDR/2016/19345.8776. Epub 2016 Nov 1.
S-1 is a novel oral fluoropyrimidine derivative, widely used for treating gastric, pancreatic, lung, head, neck and breast carcinomas. It is designed to enhance the clinical utility of an oral fluoropyrimidine and is associated with low gastrointestinal toxicity. S-1 consists of three pharmacological agents (at a molar ratio of 1:0.4:1)-Tegafur (FT), a prodrug of 5-Fluorouracil (5-FU), 5-Chloro-2-4-Dihydroxypyridine (CDHP), which inhibits the activity of Dihydropyrimidine Dehydrogenase (DPD) and Oxonic Acid (Oxo), which reduces Gastrointestinal (GI) toxicity of 5-FU. The present article reviews the current development of clinical study of S-1.
S-1是一种新型口服氟嘧啶衍生物，广泛用于治疗胃癌、胰腺癌、肺癌、头颈癌和乳腺癌。它旨在提高口服氟嘧啶的临床效用，且胃肠道毒性较低。S-1由三种药理剂（摩尔比为1:0.4:1）组成——替加氟（FT），5-氟尿嘧啶（5-FU）的前体药物；5-氯-2,4-二羟基吡啶（CDHP），可抑制二氢嘧啶脱氢酶（DPD）的活性；奥昔嘌醇（Oxo），可降低5-FU的胃肠道（GI）毒性。本文综述了S-1临床研究的当前进展。
